Figures
- FIGURE 1
25(OH)D levels in placebo and intervention groups at baseline and 12 months. Boxplots (5th percentile, 1st quartile, median, 3rd quartile and 95th percentile) showing serum 25(OH) levels (ng.mL−1) at baseline (pre; n=71 in both groups) and 12 months (post; n=61 in placebo arm and n=56 in intervention arm). No significant difference in serum 25(OH)D levels was found between the placebo and intervention arm at baseline. 25(OH)D levels were significantly higher in the intervention arm compared to the placebo arm at 12 months (p<0.001).
- FIGURE 2
Association between 25(OH)D levels and desmosine at baseline. Scatter plot showing the relationship between baseline serum 25(OH) levels (ng.mL−1) and plasma desmosine levels (µg.L−1). No significant relationship was found (p=0.842). All 142 patients from both the placebo and intervention group were included at baseline.
- FIGURE 3
Effect of vitamin D and placebo on desmosine levels. Boxplots (5th percentile, 1st quartile, median, 3rd quartile and 95th percentile) showing plasma desmosine levels (µg.L−1) in placebo and intervention arms at four time points: baseline (T=0), 4 months (T=4), 8 months (T=8) and 12 months (T=12). No significant difference in plasma desmosine levels was found between the placebo and intervention arm at any of the four time points.
- FIGURE 4
Effect of baseline 25(OH)D levels on desmosine change after vitamin D supplementation. Boxplots (5th percentile, 1st quartile, median, 3rd quartile and 95th percentile) showing the change in plasma desmosine levels (µg.L−1) over the course of the study and serum 25(OH)D levels (ng.mL−1) at baseline. A significant inverse correlation was found between the groups (p=0.002).
- FIGURE 5
Association between phosphate and desmosine levels at baseline. Scatterplot showing the association between baseline serum phosphate (mg.dL−1) and plasma desmosine levels (µg.L−1). All 142 patients from both the placebo and intervention group were included. A significant positive association was found between both variables (p<0.0001). Plasma desmosine = −0.739 + (age)*0.008 − (baseline serum phosphate)*0.233 (η2=0.157 and adjusted η2=0.145).
Tables
- TABLE 1
Baseline characteristics
Characteristic Vitamin D group Placebo group p-value Subjects n
Men71
59 (83)71
62 (87)0.482 Age years 68±9 68±8 0.649 Smoking status Current smokers 13 (18) 16 (23) 0.288 FEV1 L 1.25±0.45 1.22±0.44 0.635 FEV1 % pred 45±16 43±14 0.508 FVC L 2.82±0.80 2.95±0.88 0.377 FEV1/FVC ratio 0.44±0.12 0.42±0.11 0.239 DLCO % pred 48±17 50±16 0.538 GOLD stage I 1 (1) 0 (0) 0.319 II 21 (30) 19 (27) 0.715 III 32 (45) 38 (54) 0.317 IV 17 (24) 14 (20) 0.546 Baseline characteristics of vitamin D and placebo groups at randomisation. Both groups were matched for all given variables. Data are presented as n (%) or mean±sd, unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; GOLD: Global Initiative for Chronic Obstructive Lung Disease.
